Cargando…

Advanced pancreatic cancer with KRAS wild-type and EGFR-sensitive mutation respond favorably to furmonertinib: A case report

Pancreatic cancer is the leading cause of cancer death, and treatment options are limited and mostly ineffective. The patient we report had an EGFR exon 19 deletion and had disease progression in the short term after receiving three front-line treatment regimens. We administered furmonertinib and ob...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ma, Xiaoting, Liu, Xiu, Ou, Kai, Zhang, Manman, Gao, Lizhen, Yang, Lin
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10117981/ https://www.ncbi.nlm.nih.gov/pubmed/37091175 http://dx.doi.org/10.3389/fonc.2023.1151178

Ejemplares similares

EGFR and KRAS Mutations in Lung Parenchyma of Subjects With EGFR/KRAS Wild-Type Lung Adenocarcinoma
por: Chalela, Roberto, et al.
Publicado: (2021)

Successful therapy using high-dose furmonertinib for non-small cell lung cancer with leptomeningeal metastasis: a case report and literature review
por: Chen, Ting, et al.
Publicado: (2023)

Genomic landscape of clinically advanced KRAS wild-type pancreatic ductal adenocarcinoma
por: Ashok Kumar, Prashanth, et al.
Publicado: (2023)

Persistent response of furmonertinib plus anlotinib in a lung adenocarcinoma patient with an EGFR exon 20 insertion mutation: A case report
por: Chen, Xuesong, et al.
Publicado: (2023)

Detection of Low-Frequency KRAS Mutations in cfDNA From EGFR-Mutated NSCLC Patients After First-Line EGFR Tyrosine Kinase Inhibitors
por: Nardo, Giorgia, et al.
Publicado: (2021)

KRAS mutation testing in the treatment of metastatic colorectal cancer with anti-EGFR therapies
por: Soulières, D., et al.
Publicado: (2010)

Identification of a Rare EGFR T790I Mutation in Lung Adenocarcinoma Sensitive to Osimertinib
por: Wang, Yu, et al.
Publicado: (2021)

Case Report: Outcome of Osimertinib Treatment in Lung Adenocarcinoma Patients With Acquired KRAS Mutations
por: Xiu, Weigang, et al.
Publicado: (2021)

KRAS above and beyond – EGFR in pancreatic cancer
por: Siveke, Jens T., et al.
Publicado: (2012)

Radiomics Signature as a Predictive Factor for EGFR Mutations in Advanced Lung Adenocarcinoma
por: Hong, Duo, et al.
Publicado: (2020)

KRAS Mutations in Squamous Cell Carcinomas of the Lung
por: Acker, Fabian, et al.
Publicado: (2021)

Positive Crosstalk Between Hedgehog and NF-κB Pathways Is Dependent on KRAS Mutation in Pancreatic Ductal Adenocarcinoma
por: Wang, Yuqiong, et al.
Publicado: (2021)

KRAS and EGFR mutations coexisting in lung adenocarcinoma
por: Sousa, Vitor, et al.
Publicado: (2010)

EGFR and KRAS Mutations in Patients With Adenocarcinoma of the Lung
por: Jang, Tae Won, et al.
Publicado: (2009)

KRAS RENAISSANCE(S) in Tumor Infiltrating B Cells in Pancreatic Cancer
por: Meng, Qingda, et al.
Publicado: (2018)

The frequency of EGFR and KRAS mutations in non-small cell lung cancer (NSCLC): routine screening data for central Europe from a cohort study
por: Boch, Christian, et al.
Publicado: (2013)

EUS-FNA Biopsies to Guide Precision Medicine in Pancreatic Cancer: Results of a Pilot Study to Identify KRAS Wild-Type Tumours for Targeted Therapy
por: Lundy, Joanne, et al.
Publicado: (2021)

Furmonertinib, a Third-Generation EGFR Tyrosine Kinase Inhibitor, Overcomes Multidrug Resistance through Inhibiting ABCB1 and ABCG2 in Cancer Cells
por: Wu, Chung-Pu, et al.
Publicado: (2023)

Biomarkers That Currently Affect Clinical Practice in Lung Cancer: EGFR, ALK, MET, ROS-1, and KRAS
por: Korpanty, Grzegorz J., et al.
Publicado: (2014)

Autophagy Induced during Pancreatitis Promotes KRAS-Dependent Transformation in the Pancreas
por: Iovanna, Juan L.
Publicado: (2016)

Application progress of liquid biopsy in gastric cancer
por: Ma, Xiaoting, et al.
Publicado: (2022)

Determination of Osimertinib, Aumolertinib, and Furmonertinib in Human Plasma for Therapeutic Drug Monitoring by UPLC-MS/MS
por: Li, Ying, et al.
Publicado: (2022)

KRAS/NRAS/BRAF Mutations as Potential Targets in Multiple Myeloma
por: Pasca, Sergiu, et al.
Publicado: (2019)

Double-dose icotinib may induce the emergence of the EGFR exon 20 T790M mutation in non-small cell lung cancer patients harboring EGFR-sensitive mutation
por: Chen, Jianxin, et al.
Publicado: (2022)

Central nervous system efficacy of furmonertinib (AST2818) in patients with EGFR T790M mutated non-small cell lung cancer: a pooled analysis from two phase 2 studies
por: Hu, Xingsheng, et al.
Publicado: (2023)

EGFR p.V774M/p.L833V compound mutations in lung adenocarcinoma responded well to almonertinib: a case report
por: Pan, Hai, et al.
Publicado: (2023)

Somatic mutation detection and KRAS amplification in testicular germ cell tumors
por: Cabral, Eduardo R. M., et al.
Publicado: (2023)

High tumor mutation burden indicates better prognosis in colorectal cancer patients with KRAS mutations
por: Wang, Jianlei, et al.
Publicado: (2022)

Mutations matter: An observational study of the prognostic and predictive value of KRAS mutations in metastatic colorectal cancer
por: Lavacchi, Daniele, et al.
Publicado: (2022)

Coexistence of KRAS mutation with mutant but not wild-type EGFR predicts response to tyrosine-kinase inhibitors in human lung cancer
por: Choughule, A, et al.
Publicado: (2014)

p65BTK is a novel potential actionable target in KRAS-mutated/EGFR-wild type lung adenocarcinoma
por: Giordano, Federica, et al.
Publicado: (2019)

Triple negative breast carcinoma EGFR amplification is not associated with EGFR, Kras or ALK mutations
por: Secq, V, et al.
Publicado: (2014)

Prognostic and therapeutic impact of the KRAS G12C mutation in colorectal cancer
por: Qunaj, Lindor, et al.
Publicado: (2023)

EGFR, PIK3CA, KRAS and BRAF mutations in meningiomas
por: BUJKO, MATEUSZ, et al.
Publicado: (2014)

A Radiogenomics Ensemble to Predict EGFR and KRAS Mutations in NSCLC
por: Moreno, Silvia, et al.
Publicado: (2021)

Advanced lung adenocarcinoma patient with EGFR exon 20 insertion benefits from high-dose furmonertinib for nine months after progression from mobocertinib: a case report
por: Jia, Keyi, et al.
Publicado: (2022)

Case Report: A patient with the rare third-generation TKI-resistant mutation EGFR L718Q who responded to afatinib plus cetuximab combination therapy
por: Zhang, Guoqing, et al.
Publicado: (2022)

Detection of EGFR Mutations in Cerebrospinal Fluid of EGFR-Mutant Lung Adenocarcinoma With Brain Metastases
por: Shi, Liang, et al.
Publicado: (2021)

Dysregulation of KRAS signaling in pancreatic cancer is not associated with KRAS mutations and outcome
por: Lemstrova, Radmila, et al.
Publicado: (2017)

Counteracting gemcitabine+nab-paclitaxel induced dysbiosis in KRAS wild type and KRAS(G12D) mutated pancreatic cancer in vivo model
por: Panebianco, Concetta, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_0obfd5s38nesct8fq5lk0ltnif